Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2014

View Archived Issues

Minimizing TBI in mice by pharmacological induction of hypothermia

Direct inhibition of InhA to combat drug-resistant TB

Preclinical and phase I results presented for LY-2452473

GeNeuro presents novel clinical and preclinical results for GNbAC-1

Spring Bank Pharmaceuticals collaborates with NIH to test SB-9200

Adenium Biotech presents a novel antibacterial peptide for Gram-negative bacteria

AGI-12026, a novel potent and selective IDH2 R140Q inhibitor shows promise in vivo

Kancera updates on drugs and vaccines targeting ROR1

Alios BioPharma updates on preclinical NS5B inhibitors for HCV infection

biOasis Technologies supports new preclinical study of Transcend technology in MPS II

Telavic receives additional indication approval in Japan

Novel ROCK1 and ROCK2 inhibitors disclosed by Bristol-Myers Squibb

Purdue Pharma divulges novel Na(V)1.7 blockers for pain

Novel BRD4 inhibitors synthesized by Bristol-Myers Squibb

Transparency Life Sciences to conduct trial of Kiacta in sarcoidosis

Amgen submits BLA for BiTE immunotherapy blinatumomab

Avalon Ventures and GlaxoSmithKline launch two new companies

Researchers at Washington University disclose novel GABA(A) receptor modulators

Soligenix awarded NIAID contract to develop heat stable RiVax vaccine

Once-weekly GH replacement therapy with MOD-4023 shows promise in pediatric patients

Immunosuppressive agent Thymoglobuline approved for additional indication in Japan

Vidara Therapeutics acquired by Horizon Pharma

Kerydin launched in U.S. for onychomycosis

Noxxon's spiegelmer awarded U.S. orphan drug designation for glioblastoma

FDA and Health Canada permit expanded access administration of Tekmira's TKM-Ebola

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...